Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate
It has been proven challenging to conduct traditional efficacy trials for Ebola virus (EBOV) vaccines. In the absence of efficacy data, immunobridging is an approach to infer the likelihood of a vaccine protective effect, by translating vaccine immunogenicity in humans to a protective effect, using the relationship between vaccine immunogenicity and the desired outcome in a suitable animal model. We here propose to infer the protective effect of the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen with an 8-week interval in humans by immunobridging. Immunogenicity and protective efficacy data were obtained for Ad26.ZEBOV and MVA-BN-Filo vaccine regimens using a fully lethal EBOV Kikwit challenge model in cynomolgus monkeys (nonhuman primates [NHP]). The association between EBOV neutralizing antibodies, glycoprotein (GP)-binding antibodies, and GP-reactive T cells and survival in NHP was assessed by logistic regression analysis. Binding antibodies against the EBOV surface GP were identified as the immune parameter with the strongest correlation to survival post EBOV challenge, and used to infer the predicted protective effect of the vaccine in humans using published data from phase I studies. The human vaccine-elicited EBOV GP-binding antibody levels are in a range associated with significant protection against mortality in NHP. Based on this immunobridging analysis, the EBOV GP-specific-binding antibody levels elicited by the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen in humans will likely provide protection against EBOV disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:5 |
|---|---|
| Enthalten in: |
NPJ vaccines - 5(2020), 1 vom: 17. Dez., Seite 112 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Roozendaal, Ramon [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 21.08.2021 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1038/s41541-020-00261-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319000486 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319000486 | ||
| 003 | DE-627 | ||
| 005 | 20231225170532.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41541-020-00261-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1063.xml |
| 035 | |a (DE-627)NLM319000486 | ||
| 035 | |a (NLM)33335092 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Roozendaal, Ramon |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 21.08.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a It has been proven challenging to conduct traditional efficacy trials for Ebola virus (EBOV) vaccines. In the absence of efficacy data, immunobridging is an approach to infer the likelihood of a vaccine protective effect, by translating vaccine immunogenicity in humans to a protective effect, using the relationship between vaccine immunogenicity and the desired outcome in a suitable animal model. We here propose to infer the protective effect of the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen with an 8-week interval in humans by immunobridging. Immunogenicity and protective efficacy data were obtained for Ad26.ZEBOV and MVA-BN-Filo vaccine regimens using a fully lethal EBOV Kikwit challenge model in cynomolgus monkeys (nonhuman primates [NHP]). The association between EBOV neutralizing antibodies, glycoprotein (GP)-binding antibodies, and GP-reactive T cells and survival in NHP was assessed by logistic regression analysis. Binding antibodies against the EBOV surface GP were identified as the immune parameter with the strongest correlation to survival post EBOV challenge, and used to infer the predicted protective effect of the vaccine in humans using published data from phase I studies. The human vaccine-elicited EBOV GP-binding antibody levels are in a range associated with significant protection against mortality in NHP. Based on this immunobridging analysis, the EBOV GP-specific-binding antibody levels elicited by the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen in humans will likely provide protection against EBOV disease | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Hendriks, Jenny |e verfasserin |4 aut | |
| 700 | 1 | |a van Effelterre, Thierry |e verfasserin |4 aut | |
| 700 | 1 | |a Spiessens, Bart |e verfasserin |4 aut | |
| 700 | 1 | |a Dekking, Liesbeth |e verfasserin |4 aut | |
| 700 | 1 | |a Solforosi, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Czapska-Casey, Dominika |e verfasserin |4 aut | |
| 700 | 1 | |a Bockstal, Viki |e verfasserin |4 aut | |
| 700 | 1 | |a Stoop, Jeroen |e verfasserin |4 aut | |
| 700 | 1 | |a Splinter, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Janssen, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Baelen, Ben van |e verfasserin |4 aut | |
| 700 | 1 | |a Verbruggen, Nadia |e verfasserin |4 aut | |
| 700 | 1 | |a Serroyen, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Dekeyster, Eline |e verfasserin |4 aut | |
| 700 | 1 | |a Volkmann, Ariane |e verfasserin |4 aut | |
| 700 | 1 | |a Wollmann, Yvonne |e verfasserin |4 aut | |
| 700 | 1 | |a Carrion, Ricardo |c Jr |e verfasserin |4 aut | |
| 700 | 1 | |a Giavedoni, Luis D |e verfasserin |4 aut | |
| 700 | 1 | |a Robinson, Cynthia |e verfasserin |4 aut | |
| 700 | 1 | |a Leyssen, Maarten |e verfasserin |4 aut | |
| 700 | 1 | |a Douoguih, Macaya |e verfasserin |4 aut | |
| 700 | 1 | |a Luhn, Kerstin |e verfasserin |4 aut | |
| 700 | 1 | |a Pau, Maria Grazia |e verfasserin |4 aut | |
| 700 | 1 | |a Sadoff, Jerry |e verfasserin |4 aut | |
| 700 | 1 | |a Vandebosch, An |e verfasserin |4 aut | |
| 700 | 1 | |a Schuitemaker, Hanneke |e verfasserin |4 aut | |
| 700 | 1 | |a Zahn, Roland |e verfasserin |4 aut | |
| 700 | 1 | |a Callendret, Benoit |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t NPJ vaccines |d 2016 |g 5(2020), 1 vom: 17. Dez., Seite 112 |w (DE-627)NLM273825623 |x 2059-0105 |7 nnns |
| 773 | 1 | 8 | |g volume:5 |g year:2020 |g number:1 |g day:17 |g month:12 |g pages:112 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41541-020-00261-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 5 |j 2020 |e 1 |b 17 |c 12 |h 112 | ||